Gastric biomarkers: a global review

被引：81

作者：

Baniak, Nick ^{[1
]}

Senger, Jenna-Lynn ^{[2
]}

Ahmed, Shahid ^{[3
]}

Kanthan, S. C. ^{[4
]}

Kanthan, Rani ^{[4
]}

机构：

[1] Univ Saskatchewan, Dept Pathol & Lab Med, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada

[2] Univ Alberta, Dept Surg, 116 St & 85 Ave, Edmonton, AB T6G 2B7, Canada

[3] Univ Saskatchewan, Div Med Oncol, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada

[4] Univ Saskatchewan, Dept Gen Surg, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada

来源：

WORLD JOURNAL OF SURGICAL ONCOLOGY | 2016年 / 14卷

关键词：

Gastric cancer; Biomarkers; Therapy; HER2 GENE AMPLIFICATION; IN-SITU HYBRIDIZATION; E-CADHERIN GENE; LONG NONCODING RNAS; MICROSATELLITE INSTABILITY; CLINICOPATHOLOGICAL FEATURES; GASTROESOPHAGEAL JUNCTION; PROTEIN EXPRESSION; PHASE-II; MATRIX METALLOPROTEINASES;

D O I：

10.1186/s12957-016-0969-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Gastric cancer is an aggressive disease with a poor 5-year survival and large global burden of disease. The disease is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Despite the many prognostic, predictive, and therapeutic biomarkers investigated to date, gastric cancer continues to be detected at an advanced stage with resultant poor clinical outcomes. Main body: This is a global review of gastric biomarkers with an emphasis on HER2, E-cadherin, fibroblast growth factor receptor, mammalian target of rapamycin, and hepatocyte growth factor receptor as well as sections on microRNAs, long noncoding RNAs, matrix metalloproteinases, PD-L1, TP53, and microsatellite instability. Conclusion: A deeper understanding of the pathogenesis and biological features of gastric cancer, including the identification and characterization of diagnostic, prognostic, predictive, and therapeutic biomarkers, hopefully will provide improved clinical outcomes.

引用

页数：14

共 179 条

[51] Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas [J].

Gallardo, A. ;

Lerma, E. ;

Escuin, D. ;

Tibau, A. ;

Munoz, J. ;

Ojeda, B. ;

Barnadas, A. ;

Adrover, E. ;

Sanchez-Tejada, L. ;

Giner, D. ;

Ortiz-Martinez, F. ;

Peiro, G. .

BRITISH JOURNAL OF CANCER, 2012, 106 (08) :1367-1373

[52] E-Cadherin expression in Sporadic Gastric cancer from Mexico:: Exon 8 and 9 deletions are infrequent events associated with poor survival [J].

Gamboa-Dominguez, A ;

Dominguez-Fonseca, C ;

Chavarri-Guerra, Y ;

Vargas, R ;

Reyes-Gutierrez, E ;

Green, D ;

Quintanilla-Martinez, L ;

Luber, B ;

Busch, R ;

Becker, KF ;

Becker, I ;

Höfler, H ;

Fend, F .

HUMAN PATHOLOGY, 2005, 36 (01) :29-35

[53] Serum MicroRNAs Are Promising Novel Biomarkers [J].

Gilad, Shlomit ;

Meiri, Eti ;

Yogev, Yariv ;

Benjamin, Sima ;

Lebanony, Danit ;

Yerushalmi, Noga ;

Benjamin, Hila ;

Kushnir, Michal ;

Cholakh, Hila ;

Melamed, Nir ;

Bentwich, Zvi ;

Hod, Moshe ;

Goren, Yaron ;

Chajut, Ayelet .

PLOS ONE, 2008, 3 (09)

[54] A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond [J].

Gomez-Martin, Carlos ;

Lopez-Rios, Fernando ;

Aparicio, Jorge ;

Barriuso, Jorge ;

Garcia-Carbonero, Rocio ;

Pazo, Roberto ;

Rivera, Fernando ;

Salgado, Mercedes ;

Salud, Antonieta ;

Vazquez-Sequeiros, Enrique ;

Lordick, Florian .

CANCER LETTERS, 2014, 351 (01) :30-40

[55] HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer [J].

Gomez-Martin, Carlos ;

Garralda, Elena ;

Jose Echarri, M. ;

Ballesteros, Anabel ;

Arcediano, Alberto ;

Luis Rodriguez-Peralto, Jose ;

Hidalgo, Manuel ;

Lopez-Rios, Fernando .

JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (08) :751-757

[56] Evaluating the Consistency of Differential Expression of MicroRNA Detected in Human Cancers [J].

Gong, Xue ;

Wu, Ruihong ;

Wang, Hongwei ;

Guo, Xinwu ;

Wang, Dong ;

Gu, Yunyan ;

Zhang, Yuannv ;

Zhao, Wenyuan ;

Cheng, Lixin ;

Wang, Chenguang ;

Guo, Zheng .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (05) :752-760

[57] Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial [J].

Gordon, M. A. ;

Gundacker, H. M. ;

Benedetti, J. ;

Macdonald, J. S. ;

Baranda, J. C. ;

Levin, W. J. ;

Blanke, C. D. ;

Elatre, W. ;

Weng, P. ;

Zhou, J. Y. ;

Lenz, H. J. ;

Press, M. F. .

ANNALS OF ONCOLOGY, 2013, 24 (07) :1754-1761

[58] HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series [J].

Grabsch, Heike ;

Sivakumar, Shivan ;

Gray, Sally ;

Gabbert, Helmut E. ;

Mueller, Wolfram .

CELLULAR ONCOLOGY, 2010, 32 (1-2) :57-65

[59] Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer [J].

Grady, WM ;

Willis, J ;

Guilford, PJ ;

Dunbier, AK ;

Toro, TT ;

Lynch, H ;

Wiesner, G ;

Ferguson, K ;

Eng, C ;

Park, JG ;

Kim, SJ ;

Markowitz, S .

NATURE GENETICS, 2000, 26 (01) :16-17

[60] HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J].

Gravalos, C. ;

Jimeno, A. .

ANNALS OF ONCOLOGY, 2008, 19 (09) :1523-1529

← 1 2 3 4 5 6 7 8 9 10 →